In first, FDA approves RNA interference drug from Alnylam

The Food and Drug Administration on Friday granted the world's first approval of a drug that works by 'silencing' genes to halt disease, completing a 16-year research journey for Alnylam Pharmaceuticals, the medicine's developer.